Drug Interaction Report

Aripiprazole and Dacomitinib: Interaction Details

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Aripiprazole

Abilify Opipza
+

Dacomitinib

Vizimpro Vizimpro®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Aug 8, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 86 documented Aripiprazole interactions, 82 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Increased ARIPiprazole exposure

Interaction Deep Dive

Reduce the usual ARIPiprazole dose to 50% for patients on CYP2D6 inhibitors and to 25% for patients on dual CYP3A/CYP2D6 inhibitors1. If CYP2D6 inhibitor use exceeds 14 days, reduce ARIPiprazole IM dose 400 mg to 300 mg, 300 mg to 200 mg. With dual CYP3A/CYP2D6 inhibitors use, reduce ARIPiprazole IM dose 400 mg to 200 mg, 300 mg to 160 mg 2. Avoid ARIPiprazole, extended release 2 month injection in patients on both strong CYP3A/CYP2D6 inhibitors for over 14 days. For patients on strong CYP2D6 inhibitors, use 720 mg once every 2 months. No dosage adjustment if CYP2D6 inhibitor is taken for less than 14 days. Increase ARIPiprazole dose after stopping inhibitor 3. If coadministered, reduce Aristada(R) to the next lower strength, no dose change for 441 mg monthly if tolerated 4. Avoid, since Aristada Initio(R) dose cannot be modified 5.

Why it happens (mechanism)

Inhibition of CYP2D6-mediated metabolism of ARIPiprazole

Literature reports

1 report — tap to read

a) In a drug interaction study, concomitant use of ARIPiprazole with quiNIDine resulted in increased AUC and Cmax of ARIPiprazole by 2.1-fold and 1.1-fold, respectively. Concomitant use also increased the AUC and Cmax of dehydro-ARIPiprazole by 0.9-fold and 0.6-fold, respectively 23.

Common questions

Can I take Aripiprazole and Dacomitinib together?

Increased ARIPiprazole exposure Always confirm with your pharmacist or prescriber before making any change.

How serious is the Aripiprazole and Dacomitinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Aripiprazole or Dacomitinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (5)

  1. Product Information: ABILIFY(R) oral tablets, oral solution, intramuscular injection, aripiprazole oral tablets, oral solution, intramuscular injection. Otsuka America Pharmaceutical Inc (per FDA), Rockville, MD, 2022. DailyMed
  2. Product Information: ABILIFY MAINTENA(R) intramuscular extended-release injection, aripiprazole intramuscular extended-release injection. Otsuka America Pharmaceutical Inc (per FDA), Rockville, MD, 2020.
  3. Product Information: ABILIFY ASIMTUFII(R) intramuscular extended-release suspension, aripiprazole intramuscular extended-release suspension. Otsuka America Pharmaceutical Inc (per FDA), Rockville, MD, 2023.
  4. Product Information: ARISTADA(R) intramuscular extended-release injection, aripiprazole lauroxil intramuscular extended-release injection. Alkermes Inc (per FDA), Waltham, MA, 2018.
  5. Product Information: ARISTADA INITIO (R) intramuscular extended-release injection, aripiprazole lauroxil intramuscular extended-release injection. Alkermes, Inc (per manufacturer), Waltham, MA, 2020.
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.